364 related articles for article (PubMed ID: 33238774)
1. A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
Nichols KK; Evans DG; Karpecki PM
Curr Eye Res; 2021 May; 46(5):609-614. PubMed ID: 33238774
[TBL] [Abstract][Full Text] [Related]
2. Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program.
Chan CC; Prokopich CL
J Pharm Pharm Sci; 2019; 22(1):49-56. PubMed ID: 30636670
[TBL] [Abstract][Full Text] [Related]
3. Lifitegrast for the treatment of dry eye disease in adults.
Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
[TBL] [Abstract][Full Text] [Related]
4. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
Periman LM; Perez VL; Saban DR; Lin MC; Neri P
J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
[TBL] [Abstract][Full Text] [Related]
5. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
6. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
7. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
8. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
[TBL] [Abstract][Full Text] [Related]
9. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
Keating GM
Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
Akpek EK; Wirta DL; Downing JE; Tauber J; Sheppard JD; Ciolino JB; Meides AS; Krösser S
JAMA Ophthalmol; 2023 May; 141(5):459-466. PubMed ID: 37022717
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine Anionic and Cationic Ophthalmic Emulsions in Dry Eye Disease: A Literature Review.
Tong L; Sun CC; Yoon KC; Lim Bon Siong R; Puangsricharern V; Baudouin C
Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1606-1615. PubMed ID: 32469256
[No Abstract] [Full Text] [Related]
12. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
Karpecki P; Barghout V; Schenkel B; Huynh L; Khanal A; Mitchell B; Yenikomshian M; Zanardo E; Matossian C
BMC Ophthalmol; 2023 Nov; 23(1):443. PubMed ID: 37919692
[TBL] [Abstract][Full Text] [Related]
13. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
Holland EJ; Jackson MA; Donnenfeld E; Piccolo R; Cohen A; Barabino S; Rolando M; Figueiredo FC
JAMA Ophthalmol; 2021 Nov; 139(11):1200-1208. PubMed ID: 34617974
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
[TBL] [Abstract][Full Text] [Related]
16. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K; Stevenson OD; Mundorf TK; Reis BL
Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
[TBL] [Abstract][Full Text] [Related]
17. Sjogren's syndrome from the perspective of ophthalmology.
Kuklinski E; Asbell PA
Clin Immunol; 2017 Sep; 182():55-61. PubMed ID: 28476437
[TBL] [Abstract][Full Text] [Related]
18. Lifitegrast (Xiidra) for dry eye disease.
Med Lett Drugs Ther; 2016 Aug; 58(1502):110-1. PubMed ID: 27552207
[No Abstract] [Full Text] [Related]
19. Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
Tong AY; Passi SF; Gupta PK
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S20-S24. PubMed ID: 30985492
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review.
Holland EJ; Darvish M; Nichols KK; Jones L; Karpecki PM
Ocul Surf; 2019 Jul; 17(3):412-423. PubMed ID: 30844466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
